Immuneering Corporation

Healthcare

NASDAQ:IMRX · NASDAQ Global Market

Market Cap $152.11M Beta 0.38 P/E (TTM) -3.4

$4.19 +1.70%

+$0.07 today

52W Low $1.66High $10.08

Vol 1.54M · Avg 1.37M

EPS (TTM)-$1.24

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+120.53%

Period High

$9.26

Period Low

$1.82

Latest

$4.19

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Assembly Biosciences, Inc.

NASDAQ:ASMB

$364.90M

Nautilus Biotechnology, Inc.

NASDAQ:NAUT

$284.66M

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

$276.28M

Entrada Therapeutics, Inc.

NASDAQ:TRDA

$250.78M

Foghorn Therapeutics Inc.

NASDAQ:FHTX

$245.42M

Zura Bio Limited

NASDAQ:ZURA

$240.58M

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

$198.11M

Humacyte, Inc.

NASDAQ:HUMA

$177.24M

Tenaya Therapeutics, Inc.

NASDAQ:TNYA

$118.59M

Pyxis Oncology, Inc.

NASDAQ:PYXS

$111.51M

What is the latest IMRX filing?

The latest filing shown is 4 dated Jun 11, 2026.

How many recent filings does IMRX have?

Intrinsic Alpha currently shows 20 recent filings for IMRX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.